Glyburide treatment in gestational diabetes is associated with increased placental glucose transporter 1 expression and higher birth weight

Use of glyburide in gestational diabetes (GDM) has raised concerns about fetal and neonatal side effects, including increased birth weight. Placental nutrient transport is a key determinant of fetal growth, however the effect of glyburide on placental nutrient transporters is largely unknown. We hypothesized that glyburide treatment in GDM pregnancies is associated with increased expression of nutrient transporters in the syncytiotrophoblast plasma membranes.We collected placentas from GDM pregnancies who delivered at term and were treated with either diet modification (n  = 15) or glyburide (n = 8).

Source: Placenta - May 31, 2017 Category: Reproduction Medicine Authors: Paula D íaz, Kris Genelyn Dimasuay, Lindsey Koele-Schmidt, Brian Jang, Linda A. Barbour, Thomas Jansson, Theresa L. Powell Source Type: research